Print Page      Close Window

2018 Press Releases


Keyword Search
2018 | 2017 | 2016 | 2015
DateTitle 
12/12/18Tocagen Announces Pricing of Public Offering of Common StockPrinter Friendly Version
12/11/18Tocagen Announces Proposed Public Offering of Common StockPrinter Friendly Version
11/29/18Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed GlioblastomaPrinter Friendly Version
11/15/18Tocagen Appoints Lori Kunkel, M.D. as Acting Chief Medical OfficerPrinter Friendly Version
11/08/18Tocagen Reports Third Quarter 2018 Financial and Business ResultsPrinter Friendly Version
11/07/18Tocagen to Participate in Investor Conferences in NovemberPrinter Friendly Version
11/06/18Tocagen to Present Updated Data from Clinical and Preclinical Studies at Three Scientific and Medical ConferencesPrinter Friendly Version
11/01/18Tocagen to Report Third Quarter 2018 Financial Results on Thursday, November 8Printer Friendly Version
10/02/18Tocagen Provides Update on European Regulatory Path for Toca 511 & Toca FCPrinter Friendly Version
09/30/18Tocagen Presents Preliminary Data from Toca 6 Trial Supportive of Immune Activation in Patients with Advanced Solid Tumors at CRI-CIMT-EATI-AACR International Cancer Immunotherapy ConferencePrinter Friendly Version
09/27/18Tocagen to Participate in Four Investor Conferences in OctoberPrinter Friendly Version
09/24/18Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial OrganizationPrinter Friendly Version
09/19/18Tocagen Announces Early Completion of Enrollment in Toca 5 Pivotal Phase 3 Brain Cancer TrialPrinter Friendly Version
08/28/18Tocagen to Participate in Two Investor Conferences Next WeekPrinter Friendly Version
08/23/18Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim AnalysisPrinter Friendly Version
08/07/18Tocagen Reports Second Quarter 2018 Financial and Business ResultsPrinter Friendly Version
08/01/18Tocagen to Report Second Quarter 2018 Financial Results on Tuesday, August 7Printer Friendly Version
07/09/18Tocagen Closes Previously Announced License Agreement with ApolloBio to Develop and Commercialize Toca 511 & Toca FC in Greater ChinaPrinter Friendly Version
05/14/18Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)Printer Friendly Version
05/10/18Tocagen Reports First Quarter 2018 Financial and Business ResultsPrinter Friendly Version
05/03/18Tocagen to Report First Quarter 2018 Financial Results on Thursday, May 10Printer Friendly Version
04/19/18Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China RegionPrinter Friendly Version
04/17/18Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific ConferencesPrinter Friendly Version
04/16/18Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018Printer Friendly Version
03/15/18Tocagen to Present Preliminary Toca 6 Phase 1 Data and Immune Profiling Data at the American Association for Cancer Research (AACR) Annual Meeting 2018Printer Friendly Version
03/13/18Tocagen to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium 2018Printer Friendly Version
03/08/18Tocagen Reports Fourth Quarter and Full Year 2017 Financial and Business ResultsPrinter Friendly Version
03/07/18Tocagen Receives European Medicines Agency Orphan Medicinal Product Designation for Toca 511 & Toca FC for the Treatment of GliomaPrinter Friendly Version
03/01/18Tocagen to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress on Thursday, March 8Printer Friendly Version
02/07/18Tocagen to Present at Leerink Partners 7th Annual Global Healthcare ConferencePrinter Friendly Version